Trial Outcomes & Findings for Low-Level Laser in Head and Neck Chronic Lymphedema (NCT NCT04482855)
NCT ID: NCT04482855
Last Updated: 2024-11-19
Results Overview
Head and Neck Lymphedema and Fibrosis Assessment Criteria Change in total severity of external LEF from baseline to 8-week post-intervention visits. A larger change in this score means more reduction in the severity of external LEF. External LEF is measured by HN-LEF Assessment Criteria. The total external LEF severity score is calculated by summing the severity score of each site (total 9 sites, severity score ranging from 0-27). For each site, the severity of LEF includes no LEF (=0), mild (=1), moderate (=2), and severe (=3).
COMPLETED
NA
25 participants
Baseline, 8-week post-intervention visit
2024-11-19
Participant Flow
Participant milestones
| Measure |
Group 1 (Laser Group)
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
Low-level laser: Low-level laser therapy
|
Group 2 (Wait-list Control Group)
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
|
|---|---|---|
|
Overall Study
STARTED
|
12
|
13
|
|
Overall Study
COMPLETED
|
9
|
13
|
|
Overall Study
NOT COMPLETED
|
3
|
0
|
Reasons for withdrawal
| Measure |
Group 1 (Laser Group)
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
Low-level laser: Low-level laser therapy
|
Group 2 (Wait-list Control Group)
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
0
|
|
Overall Study
Withdrew from the study before attending the study intervention sessions due to unexpected job duty
|
1
|
0
|
|
Overall Study
Withdrew from the study before attending the study intervention sessions due to new cancer diagnosis
|
1
|
0
|
Baseline Characteristics
Low-Level Laser in Head and Neck Chronic Lymphedema
Baseline characteristics by cohort
| Measure |
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
Low-level laser: Low-level laser therapy
|
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
|
Total
n=25 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
59.5 years
STANDARD_DEVIATION 5.06 • n=99 Participants
|
62.3 years
STANDARD_DEVIATION 6.01 • n=107 Participants
|
61.0 years
STANDARD_DEVIATION 5.65 • n=206 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
22 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
12 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
24 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
12 participants
n=99 Participants
|
13 participants
n=107 Participants
|
25 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline, 8-week post-intervention visitHead and Neck Lymphedema and Fibrosis Assessment Criteria Change in total severity of external LEF from baseline to 8-week post-intervention visits. A larger change in this score means more reduction in the severity of external LEF. External LEF is measured by HN-LEF Assessment Criteria. The total external LEF severity score is calculated by summing the severity score of each site (total 9 sites, severity score ranging from 0-27). For each site, the severity of LEF includes no LEF (=0), mild (=1), moderate (=2), and severe (=3).
Outcome measures
| Measure |
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
Low-level laser: Low-level laser therapy
|
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
|
|---|---|---|
|
Total Severity of External Lymphedema and Fibrosis (LEF)
Total severity score of LEF at baseline visit
|
5.42 score on a scale
Standard Deviation 2.07
|
4.08 score on a scale
Standard Deviation 2.33
|
|
Total Severity of External Lymphedema and Fibrosis (LEF)
Total severity score of LEF at 8-week post-intervention visit
|
3.22 score on a scale
Standard Deviation 1.86
|
4.62 score on a scale
Standard Deviation 1.71
|
SECONDARY outcome
Timeframe: Baseline, 8-week post-intervention visitHead and Neck Lymphedema and Fibrosis Symptom Inventory Change in symptom burden score from baseline to 8-week post-intervention. A larger change in this score means decreased symptom burden. Symptom burden is assessed by Head and Neck Lymphedema and Fibrosis Symptom Inventory (HN-LEF SI). Higher scores (score ranging from 0-5) indicate increased symptom burden. There are 7 subscales and only one subscale (Soft Tissues and Neurologic Toxicity) score is reported here.
Outcome measures
| Measure |
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
Low-level laser: Low-level laser therapy
|
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
|
|---|---|---|
|
Symptom Burden Score: Soft Tissues and Neurologic Toxicity Subscale
Soft Tissues and Neurologic Toxicity at baseline
|
2.46 score on a scale
Standard Deviation 0.97
|
1.63 score on a scale
Standard Deviation 1.03
|
|
Symptom Burden Score: Soft Tissues and Neurologic Toxicity Subscale
Soft Tissues and Neurologic Toxicity at 8-week post-intervention visit
|
1.73 score on a scale
Standard Deviation 1.32
|
1.23 score on a scale
Standard Deviation 0.92
|
SECONDARY outcome
Timeframe: Baseline, 8-week post-intervention visitChange in neck range of motion degree from baseline to 8-week post-intervention. A larger change in this degree means better outcome with increased neck range of motion. Cervical Range of Motion Device, a valid and reliable tool, was used to measure the amount of neck movement (degrees) for the following neck movements: forward flexion, extension, right and left lateral flexion, and right and left rotation. Only right lateral rotation is reported here.
Outcome measures
| Measure |
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
Low-level laser: Low-level laser therapy
|
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
|
|---|---|---|
|
Neck Range of Motion Degree: Right Lateral Rotation
Right lateral rotation at baseline visit
|
45.38 degrees of neck movements
Standard Deviation 13.54
|
48.04 degrees of neck movements
Standard Deviation 6.98
|
|
Neck Range of Motion Degree: Right Lateral Rotation
Right lateral rotation at 8-week post-intervention visit
|
52.78 degrees of neck movements
Standard Deviation 11.18
|
47.85 degrees of neck movements
Standard Deviation 10.92
|
SECONDARY outcome
Timeframe: Baseline, 8-week post-intervention visitEORTC QLQ-H\&N35 was used to assess HNC-related quality of life. Change in EORTC QLQ-H\&N35 score from baseline to 8-week post-intervention. A larger reduction in this score means decreased symptom burden and better quality of life. The HNC-specific EORTC QLQ-H\&N35 module is a supplement, containing seven multi-item scales (pain, swallowing, senses problems, speech problems, trouble with social eating and social contact, and less sexuality) and eleven single-item scales (teeth, opening mouth, dry mouth, sticky saliva, coughing, felt ill, pain killers, nutritional supplements, feeding tube, weight loss, weight gain). The QLQ-H\&N35 scale employs a 4-point response format (''not at all" to ''very much"). Scale scores are transformed to a scale from 0 to 100 according to the EORTC scoring algorithm. For the symptoms scales, a higher score indicates a higher level of symptom burden. Only feeding tube scale is reported here.
Outcome measures
| Measure |
Group 1 (Laser Group)
n=12 Participants
Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
Low-level laser: Low-level laser therapy
|
Group 2 (Wait-list Control Group)
n=13 Participants
Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
|
|---|---|---|
|
Quality of Life Score: Feeding Tube
Quality of life -feeding tube scale score at baseline visit
|
16.67 score on a scale
Standard Deviation 38.92
|
15.38 score on a scale
Standard Deviation 37.55
|
|
Quality of Life Score: Feeding Tube
Quality of life -feeding tube scale score at 8-week post-intervention visit
|
0 score on a scale
Standard Deviation 0
|
7.69 score on a scale
Standard Deviation 27.74
|
Adverse Events
Group 1 (Laser Group)
Group 2 (Wait-list Control Group)
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Jie Deng
University of Pennsylvania School of Nursing
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place